Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SteMos1
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
SteMos1 (VRC-FLUMOS0122-00-VP) is an investigational quadrivalent universal influenza vaccine candidate developed by the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. The vaccine utilizes a self-assembling ferritin nanoparticle platform to display the highly conserved hemagglutinin (HA) stem region antigens. Unlike traditional seasonal vaccines that target the rapidly mutating HA head domain, SteMos1 is designed to elicit broad-spectrum, long-lasting immunity against a wide range of seasonal and potential pandemic influenza strains. It is currently being evaluated in a Phase 1 clinical trial (VRC 329) to assess safety and immunogenicity, both as a standalone formulation and when administered with the ALFQ (Army Liposome Formulation containing saponin QS-21) adjuvant.
- Other names
- VRC-FLUMOS0122-00-VPVRC-FLUMOS-0122-00-VPVRC-FLUMOS 0122-00-VPquadrivalent influenza HA stem vaccine
02
Targets
Group 1 HA stalk (Influenza A hemagglutinin stalk domain, group 1)HA (Hemagglutinin)
Beyond the preview
Go deeper on SteMos1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SteMos1.